查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
动物人类药物市场 - 预测 2023-2028
市场调查报告书
商品编码
1295381

动物人类药物市场 - 预测 2023-2028

Human Drugs for Veterinary Use Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 104 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

兽用人药市场预计将以 2.90% 的复合年增长率增长，从 2021 年的 33.57 亿美元增长到 2028 年的 41.02 亿美元。动物接受人类药物治疗，但它们可能会受到与人类相同的影响。儘管药物在动物身上进行了用于人类的测试，但这些影响是已知的。製药公司为人类生产的药物多于为动物生产的药物。止痛药加巴喷丁和普瑞巴林（Lyrica）在狗和马身上超说明书使用，是兽医医学中经常推荐的人类药物的例子。

此外，还使用麻醉剂，例如芬太尼、吗啡、美沙酮、氢吗啡酮、氯胺酮、丁丙诺啡和氢可酮。也可以使用曲马多，但动物的处方剂量高于人类，因为动物的代谢不同。此外，动物慢性疾病患病率的上升、生产动物数量的增加、宠物和家禽主人吸毒习惯的增加，加上人口的持续增长，正在推动增长。

宠物饲养趋势正在推动兽药行业的发展。

因此，对兽药和药品的需求将会增加。此外，研究计划资金的增加可能会推动未来几年及以后的行业扩张。抗生素耐药性是健康动物不必要地使用抗生素造成的危险。随着心臟病、糖尿病和癌症等健康问题的增加，耐药疾病的出现和传播威胁着动物治疗动物的能力。此外，随着狗和猫等动物体内寄生虫引起的疾病数量不断增加，宠物主人可能会使用抗寄生虫药物来控制和预防疾病。例如，宠物食品製造商协会(PFMA) 报告称，到2021 年，英国将有1700 万个家庭(59%) 养宠物，而PFMA 的2022 年报告指出，到2022 年，将有1740 万个家庭养宠物。此外，根据美国宠物产品协会的报告，2021年美国将有6900万狗主人和4530万猫主人。

此外，许多国家的政府都制定了严格的法律，并开展了广泛的疫苗接种和禁毒运动。例如，2022年1月，《兽药条例》生效。这是欧盟(EU) 针对抗菌素耐药性(AMR) 采取的行动，将促进创新，为兽医、农民和宠物主人提供安全、优质的药物，以管理和预防动物疾病。它支持采取新措施，提高可及性和可及性。的可用性

预计抗生素领域将占据重要的市场份额。

按药物分为抗生素、非甾体抗炎药、阿片类镇痛药、化疗药等。动物生产设施过度拥挤、卫生习惯不良以及抗生素耐药细菌的出现等因素正在增加传染病的发病率。根据《Veterinary Microbiology》杂誌上发表的一项研究，细菌性呼吸道感染在牲畜中很常见，造成经济损失和动物福利不佳。这增加了对有效抗生素来对抗这些感染和保护动物健康的需求。此外，分子生物学方法和快速POC检测等诊断技术的改进提高了准确识别和诊断牲畜细菌感染的能力。这有助于有针对性的抗生素治疗并确保适当的治疗。

由于越来越多的兽医医院提供按服务收费的治疗，北美市场正在扩大。

按地区划分，全球兽药和人用药品市场分为北美、南美、欧洲、亚太地区以及中东和非洲。美国同伴数量的增加正在加速，进一步增加了兽药的消费量。美国是认识到动物对人类药物有类似反应的先驱。用人类药物治疗动物，动物的效果与人类相似。用人类药物治疗动物，对动物的作用与对人类的作用相同。儘管动物和人类药物的生产存在差异，但用相似类型的药物治疗这些疾病也有一线希望。斯坦福大学的一项研究发现，小鼠和人类的 DNA 98% 相似。事实证明，患病的可能性是一样的。癌症、糖尿病和心臟病病例是人类和小鼠的复製品。该研究随后发表，美国联邦法律允许使用人类药物来治疗常见的人类和动物疾病。

市场趋势：

  • FDA 已批准青霉素用于兽用。
  • 2022 年 4 月，Elanco Animal Health Incorporated 和 Ginkgo Bioworks 成立了一家新公司 BiomEdit，为动物创造新的创新治疗产品。Ginkgo Bio 是美国最成功的生物技术公司之一。

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场细分
  • 货币
  • 先决条件
  • 基准年和预测年的时间表

第二章研究方法论

  • 调查数据
  • 调查过程

第三章执行摘要

  • 调查亮点

第四章市场动态

  • 市场驱动力
  • 市场製约因素
  • 波特五力分析

第五章：人用兽药市场：按药物治疗类型分类

  • 介绍
  • 抗生素
  • 非甾体抗炎药
  • 阿片类止痛药
  • 化学处理
  • 其他

6 按药物类型划分的兽用人用药品市场

  • 介绍
  • 青霉素
  • 泼尼松和泼尼松龙
  • 地西泮
  • 专业的
  • 其他

第七章人用兽药市场：按地区

  • 介绍
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 其他
  • 中东/非洲
    • 沙特阿拉伯
    • 以色列
    • 其他
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 印度尼西亚
    • 泰国
    • 台湾
    • 其他

第八章竞争格局与分析

  • 主要公司及战略分析
  • 初创企业和市场盈利能力
  • 合併、收购、协议与合作
  • 供应商竞争力矩阵

第九章公司简介

  • Merck & Co
  • Zoetis
  • Boehringer Ingelheim
  • Elanco animal health
  • Vetoquinol S.A
  • Ceva Sante Animale
  • Virbac S.A
简介目录
Product Code: KSI061612151

The human drugs for veterinary use market is expected to grow at a CAGR of 2.90% from US$3.357 billion in 2021 to US$4.102 billion by 2028. Animals are treated with human medications, which may have the same effects on them as they do on humans. While drugs are tested on animals for human use, these consequences are known. Pharmaceutical companies produce more medications for humans than for animals. Additionally, physicians treat animals with extra-label human medicines due to the disparity in industry sales and growth/ The painkillers gabapentin and pregabalin (Lyrica), used off-label in dogs and horses, are examples of human-labeled pharmaceuticals that are frequently recommended in veterinary medicine.

Additionally used are narcotics such as fentanyl, morphine, methadone, hydromorphone, ketamine, buprenorphine, and hydrocodone. Tramadol can also be employed; however, because of differences in animal metabolism, bigger doses for animals are prescribed than for humans. Moreover, the rising prevalence of chronic diseases in animals, the growing population of production animals, and an increase in drug habits among pet and poultry business owners, combined with consistent human population growth, are the factors driving the growth.

The trend toward pet ownership is driving the animal health industry.

As a result, there will be an increase in demand for animal medicines and drugs. Additionally, increased financing for research initiatives will fuel industry expansion in the ensuing years and beyond. Antibiotic resistance is a danger caused by the unnecessary use of antibiotics on healthy animals. With rising health problems like heartworm, diabetes, and cancer, the introduction and spread of drug-resistant diseases threaten the ability to treat animals. Further, the use of parasiticides by pet owners for disease management and prevention is likely to increase as cases of parasite-caused illness in dogs, cats, and other animals rise. For instance, the Pet Food Manufacturers Association (PFMA) reported that 17 million (59%) households in the United Kingdom had pets in 2021, and the PFMA 2022 report predicted that 17.4 million households had pets in 2022. Additionally, the number of dog and cat owners in the United States are 69 million and 45.3 million, respectively, in 2021, as per the American Pet Products Association report.

Further, the governments of numerous nations are putting strict laws along with widespread vaccination and drug campaigns. For instance, in January 2022, the regulation on veterinary medicinal products came into effect. It supports the European Union's (EU) action towards antimicrobial resistance (AMR) and new measures for promoting innovation and boosting accessibility and availability to safe and high-quality medications for veterinarians, farmers, and pet owners to manage and prevent animal diseases.

The antibiotics segment is expected to hold a considerable market share.

By medication, the human drugs for veterinary use market is divided into antibiotics, non-steroidal anti-inflammatories, opioid pain relievers, chemotherapeutics, and others. Factors such as overcrowding in animal production facilities, poor hygiene practices, and the emergence of antibiotic-resistant bacteria have contributed to the higher incidence of infections. According to a study published in Veterinary Microbiology, bacterial respiratory infections are common in livestock, causing economic losses and compromising animal welfare. This has increased the demand for effective antibiotics to combat these infections and safeguard animal health. Moreover, Improved diagnostic techniques, including molecular methods and rapid point-of-care tests, have enhanced the ability to identify and diagnose bacterial infections in animals accurately. This facilitates targeted antibiotic therapy and ensures appropriate treatment.

The North American market is expanding because of more veterinary facilities providing reimbursement.

By geography, the global human drug for veterinary use market has been classified into North America, South America, Europe, Asia Pacific, and Middle East, and Africa. The trend of growing companionship is increasing in the US, and the consumption of veterinary products is rising further. The United States became a pioneer in recognizing that animals might react similarly to human medicines. Animals are treated with human medications, which have the same effects on them as they do on humans. Animals are treated with human medicines, which have the same impact on them as they do on humans. Although there is a disparity in the production of drugs for animals and humans, there has been a silver lining in treating these diseases with a similar type of drug. In a study by Stanford recently, 98% DNA of a mouse and a human was found to be similar. The possibility of diseases was also found to be identical. Cases of cancer, diabetes, and heart disease were replicas of humans and mice. After that, the study was published, and the US Federal law permitted using human medicines to treat common illnesses in humans and animals.

Market Developments:

  • FDA approved the use of penicillin for animals which was earlier used only for humans.
  • In April 2022, Elanco Animal Health Incorporated and Ginkgo Bioworks launched a new company, BiomEdit, to make new and innovative treatment products for animals. Ginkgo Biotech is one of the most successful biotech companies in the US.

Market Segmentation:

By Medication Type

  • Antibiotics
  • Non-steroidal anti-inflammatories
  • Opioid pain relievers
  • Chemotherapeutics
  • Others

By Drug type

  • Penicillin
  • Prednisone and Prednisolone
  • Diazepam
  • Prozac
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
    • 4.3.6. Industry Value Chain Analysis

5. HUMAN DRUGS FOR VETERINARY USE MARKET BY MEDICATION TYPE

  • 5.1. Introduction
  • 5.2. Antibiotics
  • 5.3. Non-steroidal anti-inflammatories
  • 5.4. Opioid pain relievers
  • 5.5. Chemotherapeutics
  • 5.6. Others

6. HUMAN DRUGS FOR VETERINARY USE MARKET BY DRUG TYPE

  • 6.1. Introduction
  • 6.2. Penicillin
  • 6.3. Prednisone and Prednisolone
  • 6.4. Diazepam
  • 6.5. Prozac
  • 6.6. Others

7. HUMAN DRUGS FOR VETERINARY USE MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. UK
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Taiwan
    • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Merck & Co
  • 9.2. Zoetis
  • 9.3. Boehringer Ingelheim
  • 9.4. Elanco animal health
  • 9.5. Vetoquinol S.A
  • 9.6. Ceva Sante Animale
  • 9.7. Virbac S.A